cervical cancer
Akiram Therapeutics' CD44v6-Targeted Radiopharmaceutical to Enter Phase I Trials in Sweden
Swedish regulators cleared a clinical trial application, allowing Karolinska University Hospital investigators to begin studying 177Lu-AKIR001.
Phase II Trial of Transgene HPV-Targeted Cancer Vaccine Misses Primary Endpoint
Treatment with the vaccine did not improve progression-free survival in patients with HPV16-positive cervical and anogenital tumors.
TheraVectys Launches Phase I/IIa Trial of HPV-Targeted Vaccine in Cervical, Oropharyngeal Cancers
The trial will include patients with newly diagnosed, treatment-naïve cancers as well as those with recurrent or metastatic disease.
The firm's long-term goal is to develop targeted cancer vaccines for patients at every stage of disease, including pre-cancer.
Nykode Therapeutics Evaluating Cancer Vaccine With Tecentriq in HPV16-Positive Cervical Cancer
The double-blind trial will determine whether the cancer vaccine VB10.16 alone or combined with Tecentriq is more effective.